# US 2023/0272005 A1 · Amino Acid Sequence Derived from Sars-Cov-2 and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272005 A1
- Document ID: US20230272005A1
- Status: Published application
- Kind: A1
- Application number: 18/007,092
- Filed: 2021-07-30
- Published: 2023-08-31
- Earliest claimed: 2020-07-31
- Assignees: Toagosei Co., Ltd.; Kyoto University
- Applicants: Toagosei Co., Ltd.; Kyoto University
- Inventors: Tetsuhiko Yoshida; Nahoko Baileykobayashi; Yoshinori Yoshida
- Web page: https://patentgrep.com/patent/US20230272005A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The herein disclosed art provides amino acid sequence information that can be used to produce antibodies to protein derived from the novel coronavirus (SARS-CoV-2). Synthetic peptide having the herein disclosed amino acid sequence information is recognized as an antigen in at least one species of mammal; contains any of the following amino acid sequences: (1) MKFLVFLGIITTVAA (SEQ ID NO: 1), (2) MFVFLVLLPLVSSQC (SEQ ID NO: 2), and (3) MKIILFLALITLATC (SEQ ID NO: 3); and has a total number of amino acid residues of not more than 20.

## Claims

### Claim 1

A synthetic peptide that is recognized as an antigen in at least one species of mammal, wherein the synthetic peptide contains any of the following amino acid sequences:
(SEQ ID NO: 1)
(1) MKFLVFLGIITTVAA,
(SEQ ID NO: 2)
(2) MFVFLVLLPLVSSQC,
and
(SEQ ID NO: 3)
(3) MKIILFLALITLATC.
and has a total number of not more than 20 amino acid residues.

### Claim 2

A composition comprising a moiety that is recognized as an antigen in at least one species of mammal, wherein the composition comprises a carrier protein and a synthetic peptide having a total number of not more than 20 amino acid residues, wherein the synthetic peptide contains any of the following amino sequences:
(SEQ ID NO: 1)
(1) MKFLVFLGIITTVAA,
(SEQ ID NO: 2)
(2) MFVFLVLLPLVSSQC,
and
(SEQ ID NO: 3)
(3) MKIILFLALITLATC.

### Claim 3 (depends on 2)

The composition according to claim 2, wherein the carrier protein is bonded via a prescribed crosslinking agent to the C-terminal side or N-terminal side of the amino acid sequence given by any of SEQ ID NOs: 1 to 3.

### Claim 4

A method for producing an anti-SARS-CoV-2 antibody, wherein the antibody production method uses the amino acid information of any of the following amino acid sequences:
(SEQ ID NO: 1)
(1) MKFLVFLGIITTVAA,
(SEQ ID NO: 2)
(2) MFVFLVLLPLVSSQC,
and
(SEQ ID NO: 3)
(3) MKIILFLALITLATC.
as an antigen for producing the antibody.

### Claim 5 (depends on 4)

The method for producing the antibody according to claim 4, that uses the amino acid information of SEQ ID NO: 1.
